Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
| Autor: | Radke, Josefine, Koch, Arend, Pritsch, Fabienne, Schumann, Elisa, Misch, Martin, Hempt, Claudia, Lenz, Klaus, Löbel, Franziska, Paschereit, Fabienne, Heppner, Frank L., Vajkoczy, Peter, Koll, Randi, Onken, Julia |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Adolescent diagnosis [Glioblastoma] genetics [Glioblastoma] lcsh:RC346-429 genetics [Isocitrate Dehydrogenase] Cohort Studies Young Adult genetics [Tumor Suppressor Proteins] Predictive Value of Tests Humans ddc:610 neoplasms lcsh:Neurology. Diseases of the nervous system Aged Retrospective Studies Aged 80 and over diagnosis [Brain Neoplasms] Base Sequence Research genetics [DNA Modification Methylases] Middle Aged genetics [DNA Repair Enzymes] Pyrosequencing (PSQ) Temozolomide (TMZ) genetics [Brain Neoplasms] IDH (isocitrate dehydrogenase) Female O(6)-Methylguanine-DNA methyltransferase (MGMT) Glioblastoma Methylation specific PCR (MSP) 600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit |
| Zdroj: | Acta Neuropathologica Communications 7(1), 89 (2019). doi:10.1186/s40478-019-0745-z Acta Neuropathologica Communications Acta Neuropathologica Communications, Vol 7, Iss 1, Pp 1-9 (2019) |
| DOI: | 10.1186/s40478-019-0745-z |
| Popis: | Methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter is predictive for treatment response in glioblastoma patients. However, precise predictive cutoff values to distinguish “MGMT methylated” from “MGMT unmethylated” patients remain highly debated in terms of pyrosequencing (PSQ) analysis. We retrospectively analyzed a clinically and molecularly very well-characterized cohort of 111 IDH wildtype glioblastoma patients, who underwent gross total tumor resection and received standard Stupp treatment. Detailed clinical parameters were obtained. Predictive cutoff values for MGMT promoter methylation were determined using ROC curve analysis and survival curve comparison using Log-rank (Mantel-Cox) test. MGMT status was analyzed using pyrosequencing (PSQ), semi-quantitative methylation specific PCR (sqMSP) and direct bisulfite sequencing (dBiSeq). Highly methylated (> 20%) MGMT correlated with significantly improved progression-free survival (PFS) and overall survival (OS) in our cohort. Median PFS was 7.2 months in the unmethylated group (UM, < 10% mean methylation), 10.4 months in the low methylated group (LM, 10-20% mean methylation) and 19.83 months in the highly methylated group (HM, > 20% mean methylation). Median OS was 13.4 months for UM, 17.9 months for LM and 29.93 months for HM. Within the LM group, correlation of PSQ and sqMSP or dBiSeq was only conclusive in 51.5% of our cases. ROC curve analysis revealed superior test precision for survival if additional sqMSP results were considered (AUC = 0.76) compared to PSQ (cutoff 10%) alone (AUC = 0.67). We therefore challenge the widely used, strict PSQ cutoff at 10% which might not fully reflect the clinical response to alkylating agents and suggest applying a second method for MGMT testing (e.g. MSP) to confirm PSQ results for patients with LM MGMT levels if therapeutically relevant. Electronic supplementary material The online version of this article (10.1186/s40478-019-0745-z) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|